BioMarin Pharmaceutical Inc. reported second quarter 2026 financial results on August 6, 2026, following its April 27 acquisition of Amicus Therapeutics. Total revenues increased 20% year-over-year to $990 million, driven by new products GALAFOLD and POMBILITI + OPFOLDA alongside strong VOXZOGO demand. GAAP net income decreased 81% to $45 million due to acquisition-related costs, intangible asset amortization, and interest expense from transaction financing. The company raised its full-year 2026 total revenue guidance midpoint to $3,900 million and increased VOXZogo revenue expectations to at least $1 billion. BioMarin is a rare disease biotechnology company focused on developing and commercializing innovative medicines for genetically defined conditions.
